Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research developments
Interferon-gamma drives brain pathology in multiple system atrophy
In a new study, researchers have used a mouse model and genetic and pharmacological approaches to show that IFNγ is produced primarily by infiltrating CD4+ T-cells, and that IFNγ mediates the mechanisms that drive multiple system atrophy.
New partnership to fight dementia
The University of Dundee Drug Discovery Unit is renewing its partnership with Takeda and the University of Cambridge to discover new therapeutic treatments for dementia. The partnership will be led by Professor David Gray at the Drug Discovery Unit, Dr Will McEwan at the UK Dementia Research Institute at the University of Cambridge and Takeda, and will see the parties look for new drug-like molecules that could be taken into clinical development for Alzheimer’s Disease.
Protein modifications key influencers in neurodegenerative diseases
A new study has improved understanding of how post-translational modifications (PTMs) – changes that happen to proteins after they are synthesised in the cell – can influence the formation and pathogenicity of amyloid fibrils. The researchers say the findings suggests that modifications like O-GlcNAc could play a role in modulating the pathogenicity of alpha-synuclein, which opens up new avenues for research and potential treatments.
Company updates
Point72 buys new stake in Alto Neuroscience
Point72 Asset Management, led by prominent investment figure Steven Cohen has purchsed shares of Alto Neuroscience, establishing a 6.30% ownership in the traded company. The shares were acquired at a price of $19.39 each,
Partnership to find solutions for neurological diseases
AptarGroup is to collaborate with Biogen Inc. to enhance and manage digital health solutions for neurological and rare diseases, covering a number conditions within neurology and immunology.
Dr. Brian Ramos joins Simply Nootropics
Renowned neuroscientist Dr. Brian P. Ramos will be joining cognitive enhancement and healthy ageing supplement company Simply Nootropics as its in-house expert. Simply Nootropics has stated that the appointment of Ramos is well-aligned to boost the innovation and progress of the company.
Technology
Harnessing AI for neuroscience drug discovery and development
Alleo Labs has published a new paper that explores the increasing use of AI in developing new drugs for age-related conditions such as Alzheimer’s Disease, Parkinson’s Disease, and other chronic neurodegenerative disorders. The company has said that the publication serves as a drug hunter’s roadmap for applying machine learning to different stages of neuroscience drug discovery.
$12 million funding for AI-enhanced neurotech wearable
A group of scientists, doctors and entrepreneurs have close a $12m seed round for a first-of-its-kind wearable neurotechnology platform from neurotech health company Elemind. The platform uses proprietary algorithms and AI to improve health through noninvasive, proactive brainwave stimulation, without the side effects of pharmaceuticals.
